The development of novel therapies for rheumatoid arthritis
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disease that affects approximately 0.5 to 1 percent of the adults worldwide and commonly results in joint destruction and significant impairment in the quality of life. RA is considered as an autoimmune disease with unknown etiology. Many pathogenic pathways of RA have been revealed recently, which led to development of various novel therapies. OBJECTIVE: The current treatments of RA include 4 categories: non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, non-biologic disease-modifying anti-rheumatic drugs (DMARDs) and biologic DMARDs. In this review, we will discuss some of the most recent development in antirheumatic therapies. METHODS: Using SciFinder Scholar and PubMed as main searching tools, we evaluated various newly developed therapies for RA. Under each drug category, emphases are placed on the mode of action, limitation of the drugs and new drug candidates from the patents search. Those well-established therapies will only be reviewed briefly. CONCLUSION: During the past 20 years, most of the development of new therapies is in DMARDs, especially biological DMARDs. With the discovery of new pathways and the application of drug delivery strategies, more growth is anticipated in this research field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs
VANE, J. R. (1971) · Nature New Biology · doi:10.1038/newbio231232a0 · Cited by 8,605
Mechanisms involved in the side effects of glucocorticoids
SCHACKE, H. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00297-8 · Cited by 1,847
Klareskog, L., van der Heijde, D., de Jager, J. P., Gough, A., Kalden, J., Malaise, M., Mola, E. M., Pavelka, K., Sany, J., Settas, L., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15640-7 · Cited by 1,751
Anti-inflammatory Actions of Glucocorticoids: Molecular Mechanisms
Barnes, P. J. (1998) · Clinical Science · doi:10.1042/cs0940557 · Cited by 1,591 · cited 1×
“[38–40] Schacke et al.”
Osteoclasts are essential for TNF-α-mediated joint destruction.
Redlich, K., Hayer, S., Ricci, R., David, J.-P., Tohidast-Akrad, M., Kollias, G., Steiner, G., Smolen, J. S., Wagner, E. F., & Schett, G. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215582 · Cited by 474
Schäcke, H., Schottelius, A., Döcke, W.-D., Strehlke, P., Jaroch, S., Schmees, N., Rehwinkel, H., Hennekes, H., & Asadullah, K. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0300372101 · Cited by 466
Cited by
Phenolic compounds: Natural alternative in inflammation treatment. A Review
Ambriz-P��rez, D. L., Leyva-L��pez, N., Gutierrez-Grijalva, E. P., & Heredia, J. B. (2016) · Cogent Food & Agriculture · doi:10.1080/23311932.2015.1131412 · Cited by 333
Ramadan, G., Al-Kahtani, M. A., & El-Sayed, W. M. (2011) · Inflammation · doi:10.1007/s10753-010-9278-0 · Cited by 183
“Presently, many steroids, non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs, immunosuppressants and anti-cytokines are used to control inflammatory symptoms/pain in RA patients [10].”
Background
Metadata
- Authors
- Quan, L.-D., Thiele, G. M., Tian, J., & Wang, D.
- Venue
- Expert Opinion on Therapeutic Patents
- Publisher
- Informa UK Limited
- Published
- 2008-06-19
- Volume
- 18
- Issue
- 7
- Pages
- 723-738
- ISSN
- 1354-3776 (ISSN-L)
- 1744-7674
- OpenAlex
- W2092099033
- Cited by
- 181
- References
- 6
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The development of novel therapies for rheumatoid arthritis. https://app.cochat.ai/papers/10.1517/13543776.18.7.723
- The paper
- Quan, L.-D., Thiele, G. M., Tian, J., & Wang, D. (2008). The development of novel therapies for rheumatoid arthritis. Expert Opinion on Therapeutic Patents. https://doi.org/10.1517/13543776.18.7.723
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.